AUSTRALASIAN LEUKAEMIA AND LYMPHOMA GROUP (ALLG)
(ABN 96 066 593 100 / ACN 066 593 100)

ANNUAL RESEARCH REPORT
FOR 2000

PUBLISHED MAY 2001
CONTENTS

Foreword __________________________________________________________ 3
History of ANZLG and ALSG _________________________________________ 4
Elected members of ALLG executive subcommittees ______________________ 5
Trial Centre staff ____________________________________________________ 5
ALLG Subcommittees ________________________________________________ 6
Publications of ANZLG and ALSG ______________________________________ 7
ALLG Trials in progress and completed _________________________________ 10
  Trials completed in 2000 __________________________________________ 11-20
  Trials in progress ________________________________________________ 21-38
ALLG Sponsorship in 2000 ____________________________________________ 39
FOREWORD

This is the first research report to be prepared by the Australasian Leukaemia and Lymphoma Group (ALLG), and it is our intention that this will be an annual exercise to summarise and highlight our research achievements each year. This first report describes the activities of the Group since its formation in May 1999, and provides an overview of its diverse clinical research programs.

A history of the formation of the ALLG from the Australian and New Zealand Lymphoma Group and the Australian Leukaemia Study Group is provided on the next page. The ALLG has been formed on the basis of the strong foundation of these two clinical trials groups, both with internationally recognised track records of innovative research in leukaemia and lymphoma, and has undertaken to enhance this record of achievement. Major studies in the treatment of acute myeloid leukaemia, intermediate grade non-Hodgkin’s lymphoma, promyelocytic leukaemia, and other blood malignancies were carried forward as part of the legacy of the ANZLG and ALSG, and are discussed in this report. A variety of significant studies in other diseases are also described. These studies include those conducted by the Australasian Bone Marrow Transplant Cooperative Study Group, recognising the close association between stem cell transplantation and other forms of treatment for leukaemia and lymphoma.

As a result of the merger of the Australian and New Zealand Lymphoma Group and the Australian Leukaemia Study Group, a considerable reorganization of the operations of clinical trials activities has been required to allow efficient operation of the ALLG. A Trial Subcommittee structure has been created to “decentralize” the responsibility for the management of studies in particular disease categories. ALLG members with specific expertise and experience in particular diseases have been appointed to take charge of research activities in those areas, and to promote the general goals of the group in their respective fields. New proposals for studies will in future will be channelled through these Trial Subcommittee chairmen, who will be responsible for the overall direction of research in their area of interest. Representation of the Trial Subcommittee chairmen on the Executive Committee of the ALLG will ensure that the trials activity in their area of interest is adequately represented within the Group.

The ALLG is the major agent of clinical research in malignant diseases of the blood in Australia and New Zealand, and continues to expand its activities. A number of major collaborations with other international trials groups are an emerging feature of its activities. In addition, close relationships with major international pharmaceutical companies provide both opportunities and challenges. The interaction with these companies, and in particular the opportunities to gain access to exciting new drugs with activity in blood cancers, is the major challenge facing the ALLG.

Ken Bradstock
ALLG Chairman
HISTORY OF ANZLG AND ALSG

The Australasian Leukaemia and Lymphoma Group was formed in 1999 as a merger of the activities of 2 established clinical trials organizations, the ANZLG and the ALSG. As a result, the ALLG builds on the established reputations of the 2 groups.

The ANZLG was founded in 1973, and was initially developed as a collaborative group to investigate combination chemotherapy for intermediate grade non Hodgkins lymphoma. ANZLG was led by Dr. Ian Cooper for many years, then by Dr. Max Wolf. Membership in 1998 consisted of 159 clinicians, including haematologists, medical oncologists, and radiation oncologists. A pathology review panel was created to provide histopathology expertise for clinical studies, initially convened by Dr. Philip Ironside, then by Dr. David Ellis. The statistical and central data collection services for the ANZLG were based at the Trial Centre at the Peter MacCallum Cancer Institute in Melbourne, headed by Dr. Jane Matthews.

The publication record of the ANZLG attached at the end of this report summarizes its achievements. Major themes of research include early studies of the value of the podophylotoxin drug Teniposide in NHL; a large multicentre trial of MACOP-B compared to CHOP chemotherapy in intermediate grade NHL; an investigation of the role of Cladribine in low grade NHL; and most recently a large randomised trial of intensified chemotherapy for NHL. ANZLG participated in international cooperative studies with the Canadian National Cancer Institute, GELA, the European Bone Marrow Transplant Group, the European Organization for Research and Treatment of Cancer, and the British National Lymphoma Group.

The ALSG was formed in 1982 and initially focussed on studies in adult acute myeloid leukaemia. The group was initially led by Dr. Ray Lowenthal, then by Dr. James Bishop, and finally by Dr. Ken Bradstock. By 1998, ALSG had 120 members, predominantly haematologists, representing 48 centres. ALSG shared the same clinical trials facilities at the Peter MacCallum Cancer Institute as the ANZLG.

The ALSG conducted 2 major multicentre studies in AML between 1983 and 1991, which examined the role of intensification of induction chemotherapy. Both studies are now widely cited in the international literature on AML. ALSG also took a prominent role in the introduction of All Trans Retinoic Acid in the treatment of promyelocytic leukaemia in Australia, as well as Cladribine in the treatment of chronic lymphocytic leukaemia. International collaborations were established with European groups for trials in adult acute lymphoblastic leukaemia and CLL.
ELECTED MEMBERS OF ALLG EXECUTIVE COMMITTEE IN 2000

CHAIRMAN
Associate Professor Ken Bradstock Westmead Hospital, Sydney

VICE CHAIRMAN
Dr. Max Wolf Peter MacCallum Cancer Institute, Melbourne

SECRETARY
Associate Professor Peter Browett University of Auckland, New Zealand

TREASURER
Dr. John Seymour Peter MacCallum Cancer Institute, Melbourne

DIRECTORS
Professor David Ma St. Vincents Hospital, Sydney
Dr. Timothy Hughes Royal Adelaide Hospital, Adelaide
Dr. Paula Marlton Princess Alexandra Hospital, Brisbane
Associate Professor Jeffrey Szer Royal Melbourne Hospital, Melbourne

TRIAL CENTRE STAFF

ALLG BIOSTATISTICIAN
Dr. Jane Matthews Statistical Centre, Peter MacCallum Cancer Institute, Melbourne

ALLG CLINICAL TRIAL CO-ORDINATORS
Ms Janey Stone
Ms Heather Baxter

TRIAL CENTRE CONTACTS
Address: Statistical Centre, Peter MacCallum Cancer Institute, St Andrew's Place, East Melbourne, Victoria, 3002
or
Locked Bag 1, A'Beckett St, Victoria, 8006

Telephone: 03-9656 1265 or 03-9656 1084
Fax: 03-9656 1420
Email: lymphoma@petermac.unimelb.edu.au or leukaemia@petermac.unimleb.edu.au
ALLG TRIAL SUBCOMMITTEES

INTERMEDIATE AND HIGH GRADE NON-HODGKINS LYMPHOMA, HODGKINS DISEASE
CHAIRMEN

Dr. Max Wolf
Prof. David Ma

MYELOPROLIFERATIVE DISEASE, MYELODYSPLASIA
CHAIRMEN

Dr. Timothy Hughes
Assoc. Prof. Kerry Taylor

LOW GRADE NON-HODGKINS LYMPHOMA, MYELOMA, CHRONIC LYMPHOCYTIC LEUKAEMIA
CHAIRMEN

Dr. John Seymour
Assoc. Prof. Peter Browett

ACUTE LEUKAEMIA
CHAIRMEN

Assoc. Prof. Ken Bradstock
Dr. John Seymour

BONE MARROW TRANSPLANTATION
CHAIRMEN

Assoc. Prof. Jeffery Szer
Assoc. Prof. Ken Bradstock

LABORATORY SCIENTIFIC COMMITTEE
CHAIRMEN

Dr. Paula Marlton
Assoc. Prof. Harry Iland
PUBLICATIONS of ANZLG and ALSG

AUSTRALIAN LEUKAEMIA STUDY GROUP PUBLICATIONS


AUSTRALIAN AND NEW ZEALAND LYMPHOMA GROUP PUBLICATIONS


2. Ding JC, Cooper IA, Firkin F, Matthews JP and Robertson TI.
   Investigation of the additive potential of teniposide and vincristine in non-Hodgkin's lymphoma.
   Cancer Treatment Reports 1986; 70 (8): 985-990.

3. Benson WJ, King JC and Cooper IA. (On behalf of the ANZ Lymphoma Group).
   Abdominal CT and lymphography in the initial staging of non-Hodgkin's lymphoma.

4. Matthews JRD, Cooper IA, Matthews JP and Ding JC.
   Failure of intensive chemotherapy in poor prognosis non-Hodgkin's lymphoma.


8. Wolf M, Matthews JP, Stone J, Cooper IA, Robertson TE, Fox RM.

ALLG TRIALS COMPLETED IN 2000
INTERMEDIATE & HIGH GRADE NHL/ HODGKIN'S DISEASE

HDNHL3  Phase II study of DICE chemotherapy in lymphoma

Report Date:  18 October 2000
Accrual target:  40
Date study opened:  1997
Date 1<sup>st</sup> patient enrolled:  17/7/97
Current total accrual:  40
Expected final accrual date:  -
Date study closed to accrual:  26/4/00
Main Trial Objectives:  Toxicities, Response Rates, PFS, OS
Trial Chairman:  Miles Prince
Number of sites known (by Trial Centre) to have Ethics Committee approval:  7
Number of sites with patients entered:  5
Trial Status:  Closed to accrual
Brief details of Serious/Unexpected Adverse Events experienced to date:  Nil
Abstract, A Phase II Trial of Thalidomide in Patients with Multiple Myeloma (MM) followed by Intron-a® (Interferon Alfa-2b) Therapy. James J Biagi, H Miles Prince, Max Wolf, Henry Januszewicz, John Seymour, Andrew Grigg, Kate Lillie, Paul Mitchell, Department of Haematology, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia

Comments:  Plan to assess data in 2<sup>nd</sup> quarter of 2001.
INTERMEDIATE & HIGH GRADE NHL/ HODGKIN'S DISEASE

HDNHL1  Phase I/II Study of Irradiation with PBPCT in HD and NHL

Report Date: 17 October 2000
Accrual target: 30
Date study opened: 1997
Date 1st patient enrolled: 19/3/07
Current total accrual: 31
Expected final accrual date: -
Date study closed to accrual: 17/12/99

Main Trial Objectives: To evaluate the toxicity and efficacy of pre-and post-autograft radiotherapy to sites of bulk disease in relapsed lymphoma patients

Trial Chairman: Andrew Wirth

Number of sites known (by Trial Centre) to have Ethics Committee approval: 6

Number of sites with patients entered: 5

Trial Status: Closed to accrual, continued follow-up

Brief details of Serious/Unexpected Adverse Events experienced to date:

During pre-transplant RT: 2 patients with grade 3 haematological toxicity, no grade 4
During/after post-transplant RT: 4 patients with grade 3 haematological toxicity, no grade 4

Publications:
COSA 1999
Oral presentation accepted for International Congress of Radiation Oncology January 2001

Comments:
To be analysed in 2001.
**INTERMEDIATE & HIGH GRADE NHL/ HODGKIN'S DISEASE**

**LY1**

Multicentre evaluation of NCI protocol 89-C-41 (with minor modifications) in Burkitt’s or Burkitt-like NHL

**Report Date:** 17 October 2000  
**Accrual target:** 60 (International)  
**Date study opened:** Oct 1995 (International), 1996 (ALLG)  
**Date 1st patient enrolled:** 7/5/96  
**Current total accrual:** 88 (International), 8 (ALLG)  
**Expected final accrual date:** -  
**Date study closed to accrual:** 8/4/99  
**Main Trial Objectives:** Phase 2 study of intensive combination chemotherapy program for Burkitt’s lymphoma  
**Trial Chairman:** Joe McKendrick  
**Number of sites known (by Trial Centre) to have Ethics Committee approval:** 7  
**Number of sites with patients entered:** 6  
**Trial Status:** Closed to accrual  
**Brief details of Serious/Unexpected Adverse Events experienced to date:** Nil  
**Publications:** ASCO 1999  
**Comments:** Study conducted in collaboration with UK Lymphoma Group.
INTERMEDIATE & HIGH GRADE NHL/ HODGKIN'S DISEASE

NHL5 MACOP-B vs CHOP

Report Date: 18 October 2000

Accrual target: 300

Date study opened: 1986

Date 1st patient enrolled: 21/11/86

Current total accrual: 304

Expected final accrual date: -

Date study closed to accrual: 27/6/91

Main Trial Objectives: Randomised comparison of MACOP-B vs CHOP

Trial Chairman: Ian Cooper (Max Wolf)

Number of sites known (by Trial Centre) to have Ethics Committee approval: -

Number of sites with patients entered: 22

Trial Status: Closed to accrual. Results published. Long-term follow-up to be published

Brief details of Serious/Unexpected Adverse Events experienced to date: Nil

Publications: J Clin Oncol; 12: 769-78, 1994
Aust NZ J of Med; 24: 536-540, 1994
Presented; VI International Conference on Malignant Lymphoma, Lugano, Switzerland, 5-8 June 1996; VII international Conference on Malignant Lymphoma, Lugano, Switzerland, 2-5 June 1999

Comments: Nil
INTERMEDIATE & HIGH GRADE NHL/ HODGKIN'S DISEASE

NHL7 Phase III randomised trial of high dose CEOP + Filgrastim vs standard dose CEOP in patients with NHL

Report Date: 18 October 2000

Accrual target: 250

Date study opened: 1994

Date 1st patient enrolled: 3/3/94

Current total accrual: 250

Expected final accrual date: -

Date study closed to accrual: 25/3/99

Main Trial Objectives: Comparison of dose intensity in treatment of intermediate/high grade NHL

Trial Chairman: Max Wolf

Number of sites known (by Trial Centre) to have Ethics Committee approval: 28

Number of sites with patients entered: 25

Trial Status: Closed to accrual, follow-up continuing

Brief details of Serious/Unexpected Adverse Events experienced to date: Nil

Publications: Accepted for oral presentation at ASH 2000

Comments:
This trial was completed successfully with the target accrual of 250 patients reached in March, 1999. Analysis was performed with a median follow-up of 3.0 years and showed no significant difference in CR rate, FFS or OS. Toxicity was greater in the high-dose arm.
**INTERMEDIATE & HIGH GRADE NHL/ HODGKIN'S DISEASE**

**NHL-X3**  
**Bone marrow histology study**

<table>
<thead>
<tr>
<th><strong>Report Date:</strong></th>
<th>10 October 2000</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Accrual target:</strong></td>
<td>250</td>
</tr>
<tr>
<td><strong>Date study opened:</strong></td>
<td>Feb 1999</td>
</tr>
<tr>
<td><strong>Date 1(^{st}) patient enrolled:</strong></td>
<td>Feb 1999</td>
</tr>
<tr>
<td><strong>Current total accrual:</strong></td>
<td>200</td>
</tr>
<tr>
<td><strong>Expected final accrual date:</strong></td>
<td>-</td>
</tr>
<tr>
<td><strong>Date study closed to accrual:</strong></td>
<td>Dec 1999</td>
</tr>
<tr>
<td><strong>Main Trial Objectives:</strong></td>
<td>To study the incidence and prognostic significance of discordant marrow histology in DLCL</td>
</tr>
<tr>
<td><strong>Trial Chairman:</strong></td>
<td>Surender Juneja</td>
</tr>
<tr>
<td><strong>Number of sites known (by Trial Centre) to have Ethics Committee approval:</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Number of sites with patients entered:</strong></td>
<td>Multicentre</td>
</tr>
<tr>
<td><strong>Trial Status:</strong></td>
<td>Closed</td>
</tr>
<tr>
<td><strong>Brief details of Serious/Unexpected Adverse Events experienced to date:</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Publications:</strong></td>
<td>HSANZ 1999; ASH 1999</td>
</tr>
</tbody>
</table>

**Comments:**  
For the analysis to be completed, the primary diagnosis needs to be reviewed by the histopathology review panel. We are awaiting this analysis for approximately 20 patients. Following this review we should be able to present the final analysis at the next ALLG meeting in Melbourne in May 2001. We should also be able to present the draft of the study manuscript for discussion.
LOW GRADE NHL / MYELOMA / CLL

NHLLOW1 ASCT plus interferon in low grade NHL and mantle cell

Report Date: 19 October 2000
Accrual target: 50
Date study opened: 1995
Date 1st patient enrolled: 7/7/1995
Current total accrual: 60
Expected final accrual date: -
Date study closed to accrual: 13/5/1999

Main Trial Objectives: To examine the value of post-transplant Interferon in patients with low grade lymphoma

Trial Chairman: Andrew Grigg

Number of sites known (by Trial Centre) to have Ethics Committee approval: 12
Number of sites with patients entered: 11

Trial Status: Closed to accrual. Ongoing follow-up

Brief details of Serious/Unexpected Adverse Events experienced to date: Nil

Publications: Manuscript in preparation

Comments: Good accrual to this study
LOW GRADE NHL / MYELOMA / CLL

MM4 Australian Leukaemia Study Group protocol for patients aged 60 years or less with previously untreated myelomatosis. Induction chemotherapy with PCAB followed by high dose therapy and peripheral blood stem cell autotransplantation for young patients with myelomatosis.

Report Date: 6 October 2000

Accrual target: 50 min 100 max

Date study opened: November 1995

Date 1st patient enrolled: 17/1/1996

Current total accrual: 50

Expected final accrual date: -

Date study closed to accrual: 16/11/1999

Main Trial Objectives: To assess the efficacy and toxicity of intensified induction chemotherapy with PCAB, followed by consolidation with blood stem cell autotransplantation, in patients with untreated myeloma less than 61 years of age

Trial Chairmen: Doug Joshua / Ken Bradstock

Number of sites known (by Trial Centre) to have Ethics Committee approval: 17

Number of sites with patients entered: 12

Trial Status: Closed

Brief details of Serious/Unexpected Adverse Events experienced to date: Awaiting final analysis for full details.

Publications: Nil

Comments: Plan to analyse and publish results in the second half of 2001
**ACUTE LEUKAEMIA**

**M7**  
A randomised phase III trial to evaluate the effect of high dose vs conventional dose cytarabine in consolidation therapy following intensive induction chemotherapy supported by lenograstim (fHu G-CSF) for adult acute myeloid leukaemia

*Report Date:* 6 October 2000

*Accrual target:* 200 evaluable patients in consolidation arm

*Date study opened:* Sept 1995

*Date 1st patient enrolled:* 14/9/1995

*Current total accrual:* 206 in consolidation arm

*Expected final accrual date:* -

*Date study closed to accrual:* 27/6/2000

**Main Trial Objectives:**
1. To compare the leukaemia-free survival after consolidation therapy containing high dose cytarabine vs conventional cytarabine in AML patients induced into first remission with high dose cytarabine, idarubicin and etoposide.
2. To compare the duration of neutropenia after induction therapy in patients receiving lenograstim (G-CSF) vs no cytokine

*Trial Chairmen:* Ken Bradstock / Graham Young / Ray Lowenthal

*Number of sites known (by Trial Centre) to have Ethics Committee approval:* 29

*Number of sites with patients entered:* 26

*Trial Status:* Closed

*Brief details of Serious/Unexpected Adverse Events experienced to date:* As previously reported. Await final analysis for complete details.

*Publications:*  
Effects of Glycosylated Recombinant Human Granulocyte-Colony Stimulating Factor after High Dose Cytarabine-Based Induction Chemotherapy for Adult Acute Myeloid Leukaemia. (Submitted to Leukaemia, 2000).  

*Comments:*  
Expect to analyse results of consolidation trial in the fourth quarter of 2001.
ACUTE LEUKAEMIA

M8  A phase II study of mitozantrone and intermediate-dose cytarabine in fit patients over 60 years of age with de novo acute myeloid leukaemia

Report Date: 6 October 2000
Accrual target: 100
Date study opened: November, 1995
Date 1st patient enrolled: 15/7/1996
Current total accrual: 45
Expected final accrual date: -
Date study closed to accrual: 5/5/2000

Main Trial Objectives: To evaluate complete response rate, remission duration and overall survival in patients over 60 years with de novo AML treated with intermediate dose cytarabine and mitozantrone

Trial Chairman: Andrew Grigg

Number of sites known (by Trial Centre) to have Ethics Committee approval: 14
Number of sites with patients entered: 16

Trial Status: Closed

Brief details of Serious/Unexpected Adverse Events experienced to date: There were 4 instances of grade 4 toxicity, all in induction: 3 haematological, 1 cardiac. Besides alopecia, the grade 3 toxicities were limited to cutaneous (3 instances), N&V (4), Diarrhoea (2) and stomatitis (3) and occurred in both Induction and consolidation.

Publications: Nil

ALLG TRIALS IN PROGRESS
INTERMEDIATE & HIGH GRADE NHL/ HODGKIN'S DISEASE

HD2
Randomised trial of HDCT and ASCT vs conventional therapy for patients with advanced HD responding to first line therapy using ABVD or an ABVD-like regimen

Report Date: 19 October 2000
Accrual target: 160
Date study opened: 1993
Date 1st patient enrolled: April 1993 (International) 13/6/95 (ALLG)
Current total accrual: 191 (International 2000) 4 (ALLG)
Expected final accrual date: 2001
Date study closed to accrual: -
Main Trial Objectives: To compare elective autologous stem cell transplantation to standard chemotherapy in patients with poor prognosis Hodgkin’s disease.
Trial Chairman: Andrew Grigg
Number of sites known (by Trial Centre) to have Ethics Committee approval: 7
Number of sites with patients entered: 2
Trial Status: Open to accrual
Brief details of Serious/Unexpected Adverse Events experienced to date: Nil
Publications: Nil
Comments:
The data monitoring committee of the EBMT/Intergroup performed a second formal interim analysis of the data concerning 191 patients enrolled up to April 2000 in Paris on April 8, 2000. The meeting underlined the necessity of a continuous and accurate follow-up order to correctly measure the endpoints of the study (i.e. overall survival and relapse free survival). Finally, a further analysis of collected data has been planned for early 2000, with the aim of presenting the preliminary results of the trial during the Fifth International Symposium on Hodgkin’s disease, scheduled on September 22-26, 2001 in Cologne.
INTERMEDIATE & HIGH GRADE NHL/ HODGKIN'S DISEASE

**HD3**

Prospective study of limited chemotherapy and involved field radiotherapy for patients with clinical stage I-II Hodgkin's Disease

**Report Date:** 18 October 2000

**Accrual target:** 150

**Date study opened:** 1999

**Date 1st patient enrolled:** 10/5/1999

**Current total accrual:** 77

**Expected final accrual date:** March, 2001

**Date study closed to accrual:** -

**Main Trial Objectives:** To estimate 3 and 5 year progression-free survival after 3 (4) cycles of ABVD and IFRT in patients with early stage HD

**Trial Chairman:** Andrew Wirth

**Number of sites known (by Trial Centre) to have Ethics Committee approval:** 31

**Number of sites with patients entered:** 24

**Trial Status:** Open to accrual

**Brief details of Serious/Unexpected Adverse Events experienced to date:** Eight Serious Adverse Events have been reported in this trial since it began accrual in May 1999. Of the eight, four of the events were believed to be related to the study drugs, they included febrile neutropenia, myalgia, postural hypotension and pneumonitis.

**Publications:** Nil

**Comments:** Consideration is being given to raising the accrual target to 150.
INTERMEDIATE & HIGH GRADE NHL/ HODGKIN'S DISEASE

**HDNHL2**  
Randomised multicentre study of interferon Alfa-2b vs no treatment after intensive therapy and autologous haematopoietic stem cell transplantation for relapsing lymphoma patients

**Report Date:** 19 October 2000  
**Accrual target:** 400  
**Date study opened:** 1995 (International), 1997 (ALLG)  
**Date 1st patient enrolled:** 5/10/1995 (International), 19/8/1997 (ALLG)  
**Current total accrual:** >200 (International), 26 (ALLG)  
**Expected final accrual date:** End 2000  
**Date study closed to accrual:** -  
**Main Trial Objectives:** To examine the efficacy and toxicity of post-transplant alpha interferon in patients with relapsed lymphoma undergoing autograft  

**Trial Chairman:** Andrew Grigg  
**Number of sites known (by Trial Centre) to have Ethics Committee approval:** 8  
**Number of sites with patients entered:** 4  
**Trial Status:** Open to accrual  
**Brief details of Serious/Unexpected Adverse Events experienced to date:** Nil  
**Publications:** Nil  

**Comments:**  
Study being conducted in collaboration with GELA. Meeting in May 2000, examined interim analysis and decided to continue accrual until end of 2000.
INTERMEDIATE & HIGH GRADE NHL/ HODGKIN'S DISEASE

TROG 99.04
ALLG LY2

A non-randomised prospective study of Osteolympoma

Report Date: 4 October 2000
Accrual target: 70
Date study opened: September, 1999
Date 1st patient enrolled: N/A
Current total accrual: (2)
Expected final accrual date: 2010
Date study closed to accrual: -

Main Trial Objectives: To optimise overall survival, determine prognostic factors, avoid pathological fractures and study natural history.

Trial Chairman: David Christie

Number of sites known (by Trial Centre) to have Ethics Committee approval: 9
Number of sites with patients entered: (2)

Trial Status: Open to accrual

Brief details of Serious/Unexpected Adverse Events experienced to date: Nil

Publications: Follows on from retrospective survey (Christie et al, ANZJMed, 1999)

Comments: Two patients awaiting registration subject to eligibility checks. Funding approved from Wesley Research Institute - $300 per patient.
INTERMEDIATE & HIGH GRADE NHL/ HODGKIN'S DISEASE

NHL8  Trial to evaluate early HDCT and ABMT as part of planned initial therapy for poor risk intermediate grade NHL

Report Date:  18 October 2000
Accrual target:  500 Internationally
Date study opened:  1992
Date 1st patient enrolled:  4 December 1992 (ALLG)
Current total accrual:  425 October 1999 (International)

Expected final accrual date:  2001
Date study closed to accrual:  -
Main Trial Objectives:  To compare elective auto transplantation in first remission with standard chemotherapy in patients with poor prognosis intermediate grade NHL.

Trial Chairman:  Joe McKendrick
Number of sites known (by Trial Centre) to have Ethics Committee approval:  11
Number of sites with patients entered:  11

Trial Status:  Open to accrual
Brief details of Serious/Unexpected Adverse Events experienced to date:  Nil

Publications:  Nil
Comments:  Study being conducted in collaboration with UK Lymphoma Group.
INTERMEDIATE & HIGH GRADE NHL/ HODGKIN'S DISEASE

NHL10  MINT Trial. Randomised intergroup trial of first line treatment for patients with diffuse large B-cell NHL with a CHOP-like chemotherapy regimen with or without the anti-CD20 antibody rituximab (IDEC-C2B8)

Report Date: 18 October 2000

Accrual target: 100 (Aust)

Date study opened: September, 2000

Date 1st patient enrolled: N/A

Current total accrual: 0

Expected final accrual date: September 2002

Date study closed to accrual: -

Main Trial Objectives: To evaluate the addition of CD20 antibody to standard combination chemotherapy in untreated patients with intermediate grade NHL with low IPI.

Trial Chairman: David Ma / Devinder Gill

Number of sites known (by Trial Centre) to have Ethics Committee approval: 12 with Ethics approval, 2 activated

Number of sites with patients entered: 0

Trial Status: Open to accrual

Brief details of Serious/Unexpected Adverse Events experienced to date: Nil

Publications: Nil

Comments: Study being conducted in collaboration with the German High Grade Non-Hodgkin’s Lymphoma Study Group and approximately 11 other groups internationally.
LOW GRADE NHL / MYELOMA / CLL

CLL2

International phase 3 trial of primary therapy for B-Cell chronic lymphocytic leukaemia.

Report Date: 6 October 2000

Accrual target: 500 International

Date study opened: November 1998 (Aust)
15 November 1997 (International)

Date 1st patient enrolled: 26 March, 1999 (Aust)
25 November, 1999 (International)

Current total accrual: 30 (Aust)
93 (International)

Expected final accrual date: 31 March 2003 (International)

Date study closed to accrual: -

Main Trial Objectives: To evaluate the efficacy and toxicity of chlorambucil, fludarabine and cladribine, as primary treatment of previously untreated patients with symptomatic B-cell CLL.

Trial Chairman: Stephen Mulligan

Number of sites known (by Trial Centre) to have Ethics Committee approval: 16

Number of sites with patients entered: 14

Trial Status: Open to accrual

Brief details of Serious/Unexpected Adverse Events experienced to date: 30 patients have been entered in Australia of which 6 have been randomised a second time according to protocol. SAE’s include severe cutaneous reaction to one of the protocol drugs.

Publications: Nil

Comments: International collaborative trial with Scandinavian and British investigators.
LOW GRADE NHL / MYELOMA / CLL

NHLLOW4  CHOP ± MabThera in relapsed follicular NHL

Report Date:  19 October 2000

Accrual target:  152 (Internationally)
                100 (ALLG)

Date study opened:  1999

Date 1st patient enrolled:  1 February 1999

Current total accrual:  71 (International)
                        21 (ALLG)

Expected final accrual date:  2001

Date study closed to accrual:  -

Main Trial Objectives:  Randomised study of CHOP +/- MabThera. The objectives are to determine the effect of addition of MabThera to CHOP in relapsed low-grade NHL on response and to determine the effect of maintenance MabThera on progression-free survival.

Trial Chairman:  Max Wolf

Number of sites known (by Trial Centre) to have Ethics Committee approval:  39

Number of sites with patients entered:  12

Trial Status:  Open to accrual. Protocol recently amended.

Brief details of Serious/Unexpected Adverse Events experienced to date:  International summary of SAE’s received by EORTC Safety Desk by September 2000 indicates that there have been 14 events comprising 17 conditions (3 events involved 2 conditions each). One patient has died, 1 had a life threatening event, 11 were hospitalised and 1 experienced a disability. Six events were coded as definitely or probably related to treatment consisting of one each of: infection, allergy, febrile neutropenia, hyperglycemia, delayed neutropenia and hypocalcemia.

Publications:  Nil

Comments:  Study conducted in collaboration with EORTC and 6 other cooperative groups internationally. Poor accrual internationally. Recent amendment (EORTC Amendment 4) improves the eligibility criteria and hopefully will result in an improved accrual.
**LOW GRADE NHL / MYELOMA / CLL**

**TROG99.03**

A randomised multicentre trial of involved field radiotherapy versus involved field radiotherapy plus chemotherapy for stage I-II low grade follicular lymphoma

Report Date: 19 October 2000

Accrual target: 200

Date study opened: August 1999

Date 1st patient enrolled: 14 February 2000

Current total accrual: 2

Expected final accrual date: December 2005

Date study closed to accrual: -

Main Trial Objectives:

Primary Objective:
- Study effect of CVP x 6 on progression-free survival in Stage I-II low grade FL treated with IFRT

Secondary Endpoints:
- t(14;18): Value of “molecular remission”
- Overall survival
- Toxicity
- Patterns of failure
- Transformation

Trial Chairman: Michael MacManus

John Seymour

Number of sites known (by Trial Centre) to have Ethics Committee approval: 15

Number of sites with patients entered: 1

Trial Status: Open to accrual

Brief details of Serious/Unexpected Adverse Events experienced to date: Nil

Publications: Nil

Comments: Early accrual slow.
MYELOPROLIFERATIVE DISEASE / MYELODYSPLASIA

YNK01 / Intron study in CML

Report Date: October 2000
Accrual target: 64 (evaluable in 1A/1B)
Date study opened: December 1997
Date 1st patient enrolled: December 1997
Current total accrual: 2x32 EVA
Expected final accrual date: Uncertain
Date study closed to accrual: -
Main Trial Objectives: To examine efficacy of YNK01 and Intron-A in de novo chronic myeloid leukaemia

Trial Chairman: Kerry Taylor
Number of sites known (by Trial Centre) to have Ethics Committee approval: 12
Number of sites with patients entered: 12

Trial Status: Trial was conducted on two consecutive cohorts:
1A - intermittent YNK01 – reached accrual
1B - continuing accrual

Brief details of Serious/Unexpected Adverse Events experienced to date:
Toxicity has included aesthenia, gastrointestinal intolerance, cytopenias and hepatitis (see ASH 2000)

Publications:

Comments:
Accrual to 1B has been slow due to competing STI studies.
ETI(PT1) A MRC randomised trial to compare aspirin vs hydroxyurea/aspirin in “immediate risk” primary thrombocythaemia and hydroxyurea/aspirin vs anagrelide/aspirin in “high risk” primary thrombocythaemia

Report Date: 6 October 2000
Accrual target: 600 patients in each risk group
Date study opened: June 1997
Date 1st patient enrolled: 4 August 1997 (Australia)
21 July 1997 (International)
Current total accrual: 21 (Australia)
581 (International)
Expected final accrual date: July 2002
Date study closed to accrual: -
Main Trial Objectives: To define the natural history and optimal treatment of various risk groups of primary thrombocythaemia.

Trial Chairman: Andrew Grigg
Number of sites known (by Trial Centre) to have Ethics Committee approval: 8
Number of sites with patients entered: 5

Trial Status: Open to accrual
Brief details of Serious/Unexpected Adverse Events experienced to date: None thus far

Publications: None thus far

Comments:
Australian accrual is 21 patients: low risk - 6, intermediate risk - 6, high risk - 10.
International accrual is 581 patients: low risk - 39, intermediate risk - 76, high risk - 491. This total of 581 patients includes 25 patients who have been re-randomised: low to intermediate risk - 6, intermediate to high risk - 18.
ACUTE LEUKAEMIA

APML3 A phase 2 trial in patients with acute promyelocytic leukaemia to evaluate the effects of:
1. All-trans retinoic acid combined with intensive idarubicin during induction and consolidation;
2. Subsequent intermittent all-trans retinoic acid; and,
3. Molecular monitoring for evidence of minimal residual leukaemia and for evidence of incipient relapse

Report Date: 6 October 2000
Accrual target: 100
Date study opened: June 1997
Date 1st patient enrolled: 19 August 1997
Current total accrual: 59
Expected final accrual date: Mid 2002
Date study closed to accrual: -

Main Trial Objectives: To maximise the complete remission rate by combining all-trans retinoic acid (ATRA) with intensive idarubicin chemotherapy, to minimise relapse rate by employing a second course of idarubicin followed by intermittent ATRA for eradication of minimal residual leukaemia, and to maximise overall survival through an intensive program of molecular monitoring for the detection of incipient relapse combined with an aggressive therapeutic intervention strategy aimed at eradication of low levels of recurrent leukaemia.

Trial Chairmen: Harry Iland / Jim Wiley / Frank Firkin

Number of sites known (by Trial Centre) to have Ethics Committee approval: 26
Number of sites with patients entered: 23

Trial Status: Open to accrual

Brief details of Serious/Unexpected Adverse Events experienced to date: - First 42 patients reviewed in May 2000
- Four early deaths during induction with Idarubicin #1
- One death during consolidation after Idarubicin #2
- Grade 3-4 cardiotoxicity in 5 patients (4 after Idarubicin #1, 1 after Idarubicin #2
- Two patients withdrawn from study (1 resistant disease, 1 cardiotoxicity)
ACUTE LEUKAEMIA

APML3 (Contd)

A phase 2 trial in patients with acute promyelocytic leukaemia to evaluate the effects of:
1. All-trans retinoic acid combined with intensive idarubicin during induction and consolidation;
2. Subsequent intermittent all-trans retinoic acid; and,
3. Molecular monitoring for evidence of minimal residual leukaemia and for evidence of incipient relapse

Publications: Nil but presented in part at MRD Symposium at HSANZ Annual Meeting, Perth 2000

Comments: Maintenance program added for ALLG meeting in May 2000 because of higher than expected incidence of molecular relapse.
ACUTE LEUKAEMIA

ALL2 - A multicentre trial of induction and post-remission therapy of adult acute lymphoblastic leukaemia
LALA94

Report Date: 6 October 2000
Accrual target: 1000 (worldwide, induction)
Date study opened: June 1994 (November 1995 in Australia)
Date 1st patient enrolled: June 1994 (27 November 1995 in Australia)
Current total accrual: 865 (65 ALLG)
Expected final accrual date: Mid July 2001
Date study closed to accrual: -

Main Trial Objectives: This is a complex trial examining several risk-stratified questions in induction and consolidation therapy for adult ALL. In the induction phase, there was a comparison of the anthracyclines Daunorubicin and Idarubicin. Post-induction, in standard risk patients, there is a comparison of two chemotherapy regimens for consolidation therapy. In high-risk patients, a comparison of maintenance chemotherapy with early autologous stem cell transplantation is being carried out in patients lacking a histocompatible sibling donor.

Trial Chairmen: Denis Fiere (France) / Ken Bradstock

Number of sites known (by Trial Centre) to have Ethics Committee approval: 8

Number of sites with patients entered: 8

Trial Status: Open for accrual. Induction anthracycline randomisation Closed.

Brief details of Serious/Unexpected Adverse Events experienced to date: No unexpected serious toxicities identified at last review meeting April 1999.

Publications: Nil

Comments: International collaborative study with French Adult ALL Group.
BONE MARROW TRANSPLANTATION

Mini allograft study in chronic myeloid leukaemia and myeloma

Report Date: 26 October 2000

Accrual target: 40

Date study opened: January 1999

Date 1st patient enrolled: 18 August 1999

Current total accrual: 23

Expected final accrual date: December 2001

Date study closed to accrual: -

Main Trial Objectives: To assess the timing and characteristics of donor engraftment in patients receiving T-cell depleted peripheral blood stem cell allografts after non-myeloablative conditioning therapy.

Trial Chairmen: Tim Hughes / Peter Bardy

Number of sites known (by Trial Centre) to have Ethics Committee approval: 7

Number of sites with patients entered: 5

Trial Status: Currently accruing

Brief details of Serious/Unexpected Adverse events experienced to date: Unexpected high rejection rate in myeloma and high relapse rate in CML.

Publications: EBMT 2000 oral presentation ASH 2000 poster

Comments: Study modified to increase T cell dose and to reduce intensity of conditioning therapy.
## BONE MARROW TRANSPLANTATION

### Pamidronate post allogeneic bone marrow transplantation

<table>
<thead>
<tr>
<th><strong>Report Date:</strong></th>
<th>25 October 2000</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Accrual target:</strong></td>
<td>100</td>
</tr>
<tr>
<td><strong>Date study opened:</strong></td>
<td>March 1999</td>
</tr>
<tr>
<td><strong>Date 1st patient enrolled:</strong></td>
<td>March 1999</td>
</tr>
<tr>
<td><strong>Current total accrual:</strong></td>
<td>65</td>
</tr>
<tr>
<td><strong>Expected final accrual date:</strong></td>
<td>June 2001</td>
</tr>
<tr>
<td><strong>Date study closed to accrual:</strong></td>
<td>-</td>
</tr>
<tr>
<td><strong>Main Trial Objectives:</strong></td>
<td>To assess whether pamidronate prevents loss of BM density after allo BMT</td>
</tr>
<tr>
<td><strong>Trial Chairmen:</strong></td>
<td>Andrew Grigg</td>
</tr>
<tr>
<td><strong>Number of sites known (by Trial Centre) to have Ethics Committee approval:</strong></td>
<td>5</td>
</tr>
<tr>
<td><strong>Number of sites with patients entered:</strong></td>
<td>4</td>
</tr>
<tr>
<td><strong>Trial Status:</strong></td>
<td>Ongoing, accruing well</td>
</tr>
<tr>
<td><strong>Brief details of Serious/Unexpected Adverse events experienced to date:</strong></td>
<td>Hypocalcaemia; prevented by prior Ca$^2+$ supplementation</td>
</tr>
<tr>
<td><strong>Publications:</strong></td>
<td>Nil, too early. No analyses yet.</td>
</tr>
<tr>
<td><strong>Comments:</strong></td>
<td>Good study</td>
</tr>
</tbody>
</table>
# BONE MARROW TRANSPLANTATION

## MabThera post autograft for mantle cell lymphoma

<table>
<thead>
<tr>
<th><strong>Report Date:</strong></th>
<th>25 October 2000</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Accrual target:</strong></td>
<td>12 (initially)</td>
</tr>
<tr>
<td><strong>Date study opened:</strong></td>
<td>May 1999</td>
</tr>
<tr>
<td><strong>Date 1st patient enrolled:</strong></td>
<td>June 1999</td>
</tr>
<tr>
<td><strong>Current total accrual:</strong></td>
<td>8</td>
</tr>
<tr>
<td><strong>Expected final accrual date:</strong></td>
<td>August 2001</td>
</tr>
<tr>
<td><strong>Date study closed to accrual:</strong></td>
<td>-</td>
</tr>
<tr>
<td><strong>Main Trial Objectives:</strong></td>
<td>To assess the tolerability of MabThera post autograft; molecular analysis as a secondary end-point</td>
</tr>
<tr>
<td><strong>Trial Chairmen:</strong></td>
<td>Andrew Grigg</td>
</tr>
<tr>
<td><strong>Number of sites known (by Trial Centre) to have Ethics Committee approval:</strong></td>
<td>8</td>
</tr>
<tr>
<td><strong>Number of sites with patients entered:</strong></td>
<td>5</td>
</tr>
<tr>
<td><strong>Trial Status:</strong></td>
<td>Ongoing</td>
</tr>
<tr>
<td><strong>Brief details of Serious/Unexpected Adverse events experienced to date:</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Publications:</strong></td>
<td>Nil</td>
</tr>
<tr>
<td><strong>Comments:</strong></td>
<td>Ongoing trial; limited molecular data</td>
</tr>
</tbody>
</table>
ALLG SPONSORSHIP IN 2000

The ALLG gratefully acknowledges the financial support of the following pharmaceutical companies and other funding bodies during 2000:

**Pharmaceutical company support**

**Meeting sponsorship**

**Major sponsors**
Amgen Australia
Novartis
Roche Australia

**Standard sponsors**
Amrad Novartis
Amrad NZ Pfizer
Asta Medica Pharmacia & Upjohn
Covance (representing Maxim Pharmaceuticals) Roche
CSL Schering
Glaxo-Wellcome Schering-Plough
Janssen-Cilag Schering-Plough NZ
NeXstar Wyeth

**Trial support**
Amgen Australia
Amrad
Asta Medica
Janssen-Cilag
Pharmacia
Roche
Schering-Plough
Wyeth

**Other financial support**

National Health and Medical Research Council of Australia
Medical Research Council (UK)